← Back to news
Clinical trialRSSWednesday, April 22, 2026 · 2 days ago

AAN 2026: Switch to Vyalev stops troublesome dyskinesia in trial

WHY IT MATTERS

If you have Parkinson's disease and experience dyskinesia from your current levodopa treatment, switching to Vyalev could eliminate these involuntary movements within months rather than managing them as a permanent side effect.

A new medication called Vyalev helped people with Parkinson's disease stop experiencing unwanted, uncontrolled movements (called dyskinesia) when they switched to it from other Parkinson's drugs. In two clinical trials, most people saw these troublesome movements go away within a few months of starting Vyalev. This is good news because dyskinesia is a common side effect that happens after taking Parkinson's medications for a long time.

People with Parkinson’s disease who switch from other levodopa/carbidopa formulations to Vyalev (foscarbidopa and foslevodopa) usually see uncontrolled movements stop within a few months of making the switch, according to a new analysis of data from two clinical trials. A team including scientists at AbbVie, the company that sells Vyalev, presented the analysis at this […] The post AAN 2026: Switch to Vyalev stops troublesome dyskinesia in trial appeared first on Parkinson's New

ASK YOUR DOCTOR

Ask your neurologist at your next appointment whether switching to Vyalev might be appropriate for you, especially if dyskinesia is affecting your quality of life.

Find a specialist →Learn more ↗
parkinson's diseasedyskinesialevodopatreatment switchclinical trial

Related conditions

Addison diseaseHereditary late-onset Parkinson diseaseAllergic bronchopulmonary aspergillosis